Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
about
Beyond taxanes: the next generation of microtubule-targeting agentsIxabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialGene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cellsSUMOylation inhibits FOXM1 activity and delays mitotic transition.SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathwayPrognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells.Preclinical profile of cabazitaxel.Ixabepilone development across the breast cancer continuum: a paradigm shift.Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive valueGambogenic acid alters chemosensitivity of breast cancer cells to AdriamycinDemethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.A marine anthraquinone SZ-685C overrides adriamycin-resistance in breast cancer cells through suppressing Akt signalingMicrovessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients groupRandomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinaseTreatment options for breast cancer resistant to anthracycline and taxaneMultiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cellsNew oral anticoagulants and the cancer patient.Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells.Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review.Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients.Identifying differentially expressed genes from cross-site integrated data based on relative expression orderings.Emerging drugs in metastatic breast cancer
P2860
Q26865369-842F47BA-B126-49C2-B52D-84E5ACA2DB61Q28534786-95ADC0E2-C866-4601-B677-C614232DDC98Q28542669-53555521-2DF1-45C5-A47F-89CB4C5E25A0Q30583585-31C246FA-0A5B-4FF7-A3F0-C61D0BEB6013Q33685963-CF1A0178-7DD9-4F7F-B5AB-AF51B54BC4C9Q33700800-2368F323-1FC1-49F8-B511-BB6517B64DFCQ34148034-21EC2317-EA8B-430A-B3EE-1EB490E34E9BQ34394251-CA4D5684-D2CB-4031-96E5-2F17BCF6606EQ34417996-AA8BFEBF-202B-4C82-AEEE-2CD4E2240065Q35503492-CA31309B-36FB-4346-BD02-26C2447713F6Q35661283-7164A95E-D769-429D-9054-4774D9B624F4Q35820013-FF4518AE-14CF-482F-9D72-EDDA33A10CCAQ36006475-1A79B143-54C6-4A76-B41B-E5097971A3D8Q36250209-19D5DC5C-9EDB-47D3-ACBA-1888005917A2Q36410270-6D4DAA9C-AAFE-4F29-BEC3-C252E831E069Q36747293-5ECA3A77-D8BE-47F8-B575-B8A156F79918Q37207961-BA4DC418-59CE-4537-BDA6-0F98AAA80116Q37511825-360BC47D-CCDE-41BB-A1B2-41B4103ECB28Q37519054-60D8A788-4E44-4565-9D69-9458E28FD378Q38454847-D0DCC0F2-7CB0-4ACC-90BA-95A9975E21C7Q38576762-E779EEAB-AE33-4DAB-B197-90B647D1CD1AQ39303893-6167BC40-2DFC-45A1-8805-E82D07C6D37CQ47787078-397A69E2-7E7E-4867-8B14-4188ACC59AD3Q53183757-7D82ABC3-8FE8-474A-B48E-22BC84EA7110Q55475012-44CA1E39-EF34-440D-9A67-45E3D28B54AEQ57142532-13D23EFF-9BCD-4D61-BD68-C29B4D06A2E5
P2860
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cellular mechanisms of resista ...... ancer: intrinsic and acquired.
@en
Cellular mechanisms of resista ...... ancer: intrinsic and acquired.
@nl
type
label
Cellular mechanisms of resista ...... ancer: intrinsic and acquired.
@en
Cellular mechanisms of resista ...... ancer: intrinsic and acquired.
@nl
prefLabel
Cellular mechanisms of resista ...... ancer: intrinsic and acquired.
@en
Cellular mechanisms of resista ...... ancer: intrinsic and acquired.
@nl
P1433
P1476
Cellular mechanisms of resista ...... ancer: intrinsic and acquired.
@en
P2093
A Jo Chien
Mark M Moasser
P304
S1-S14; quiz S39
P356
10.1053/J.SEMINONCOL.2008.02.010
P433
P577
2008-04-01T00:00:00Z